Elsevier

Journal of Psychiatric Research

Volume 80, September 2016, Pages 14-21
Journal of Psychiatric Research

Could cannabidiol be used as an alternative to antipsychotics?

https://doi.org/10.1016/j.jpsychires.2016.05.013Get rights and content

Highlights

  • Antipsychotics failed to meet expectations because of their severe side effects.

  • The endocannabinoid system is increasingly recognized as having a role in schizophrenia.

  • Herein, I review the antipsychotic effects of CBD in clinical trials and animal models of schizophrenia.

  • CBD exhibits potent antipsychotic properties and a superior side-effect profile.

Abstract

Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the study of compounds that can modulate its activity for therapeutic purposes. Among them, cannabidiol (CBD), a non-psychoactive component of cannabis, shows great promise for the treatment of psychosis, and is associated with fewer extrapyramidal side effects than conventional antipsychotic drugs. The overarching goal of this review is to provide current available knowledge on the role of the dopamine system and the ECS in schizophrenia, and to discuss key findings from animal studies and clinical trials investigating the antipsychotic potential of CBD.

Introduction

Schizophrenia is a complex mental health disorder that poses serious complications to the individual and to the society in terms of health care costs. This disease typically leads to low quality of life, long term disability, and reduced ability to work (Makinen et al., 2008). The median lifetime prevalence and incidence of schizophrenia are estimated at 0.72% and 15.2 per 100 000 individuals a year respectively (McGrath et al., 2008). However, the relative risk of this disease varies greatly across different locations and ethnicity, and has been shown to be particularly elevated among migrant group (Bhugra, 2004, Bhugra and Becker, 2005). Symptoms of schizophrenia usually emerge during adolescence and early adulthood, and are clustered into tree main categories; negative, positive, and cognitive. Negative symptoms, which are some of the most difficult to diagnose, refer to reduced emotional and behavioral response (Patel et al., 2014). Among them, blunted affect and anhedonia are the most strongly manifested in schizophrenic patients, but other symptoms such as reduced motivation and social interaction are also commonly observed (Makinen et al., 2008). In contrast to negative symptoms, positive symptoms are generally more easily identified. They are characterized by hallucinations, delusion, disorganized thinking and movement disturbances (Patel et al., 2014). Finally, cognitive deficits in schizophrenia include reduced episodic memory, poor executive functioning, low processing speed and disorganized speech, ultimately impairing the ability of the individual to properly think and communicate (Patel et al., 2014, Sheffield et al., 2014).

One of the most studied and recognized model of schizophrenia is the dopamine hypothesis (Howes and Kapur, 2009). This model attributes the symptoms of the disease to a hyperfunction of dopaminergic signaling in the mesolimbic system. It draws evidence from the observation that a large number of antipsychotics have the ability to block dopamine D2 receptors (Seeman and Lee, 1975, Howes and Kapur, 2009). Antipsychotics are divided into two classes: the typical (or first generation) and the atypical (or second generation). Although being efficient in managing some symptoms of schizophrenia, treatment with typical antipsychotics usually results in extrapyramidal side effects such as spasticity and tardive dyskinesia (Tandon and Jibson, 2002), whereas treatment with atypical antipsychotics leads to severe complications including weight gain, sedation and hyperlipidemia (Ucok and Gaebel, 2008).

Besides the dopamine hypothesis, evidence also support the notion that a dysregulation of the endocannabinoid system (ECS) may be linked to the pathophysiology of schizophrenia. The ECS is a signaling system that is mainly composed of the cannabinoid receptors types 1 (CB1) and type 2 (CB2), the endogenous ligands N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), as well as the hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (Parsons and Hurd, 2015). Evidence supporting the role of the ECS in schizophrenia comes in part from post-mortem, imaging, and neurochemical studies showing abnormal brain levels of cannabinoid receptors and endocannabinoid ligands during the course of schizophrenia (Vigano et al., 2009, Dalton et al., 2011, Muguruza et al., 2013). Namely, some studies have shown that patients with schizophrenia-like symptoms have increased endocannabinoid signaling as a result of higher cannabinoid receptor density in certain brain areas (Dalton et al., 2011, Jenko et al., 2012). In addition, chronic administration of delta-9-tetrahydrocannabinol (THC), which acts as an agonist to cannabinoid receptors, was shown to precipitate the occurrence of schizophrenia-like symptoms in healthy subjects (D’Souza et al., 2004), and exacerbate the core psychotic and cognitive deficits in antipsychotic-treated schizophrenic patients (D’Souza et al., 2005). These findings led to the formulation of the “cannabinoid hypothesis of schizophrenia”, which speculates that a hyperactivity of the ECS may contribute to the development of schizophrenia-like symptoms. As such, the use of compounds that modulate its activity could have a tremendous potential for therapeutic interventions. One such compound is cannabidiol (CBD), a non-psychotropic component of cannabis. CBD was recently suggested as a promising antipsychotic agent because of its ability to prevent the actions of THC, the main constituent of cannabis (Niesink and van Laar, 2013). However, despite recent advances in research, the antipsychotic effects of CBD are not fully understood, and there are still debates as to whether this compound should be used as a treatment for schizophrenic patients.

The aim of this review is to provide a better understanding of the current treatment approaches used for schizophrenia, and to discuss whether CBD could be used as an effective line of treatment for this debilitating disease. This review first starts by describing evidence supporting a role for dopamine and endocannabinoids in schizophrenia, and provides an overview of the most commonly encountered side effects associated with currently used antipsychotics. This paper also draws on findings of animal studies and clinical trials exploring the therapeutic profile of CBD in schizophrenia, and discusses whether this compound could be used as an alternative to antipsychotics.

Section snippets

Dopamine in schizophrenia

The two dopaminergic pathways that are implicated in the onset of schizophrenia-like symptoms are the mesolimbic and mesocortical pathways. The mesolimbic pathway is comprised of dopaminergic projections that originate from the ventral tegmental area (VTA), and that innervate regions of the brain like the nucleus accumbens (NAc), which plays a key role in regulating the positive symptoms of schizophrenia. On the other hand, the mesocortical dopaminergic pathway is involved in emotional and

Typical and atypical antipsychotics: the end of an era?

Typical and atypical antipsychotics are currently the two main types of medication used for the treatment of schizophrenia. They both have a successful track record in treating hallucinations, paranoia, and other symptoms of schizophrenia. Atypical antipsychotics are currently considered a better option than conventional drugs because they are less prone to induce secondary motor effects, and are associated with overall improved subjective experience and compliance to treatment regimen (Lambert

The ECS in schizophrenia

Because of major issues related to the use of antipsychotics, several studies have explored neurotransmitter systems outside of the standard dopamine hypothesis that could have potential implications in schizophrenia. One such system is the ECS. The belief that the ECS might be implicated in schizophrenia symptomatology comes from longitudinal studies suggesting that chronic exposure to cannabis, especially during adolescence, increases the risk of psychotic and schizophrenia-like symptoms

CBD: a promising antipsychotic medication?

Since the discovery of cannabinoid receptors and endogenous ligands, there has been growing interest in exploring the ECS as a new target for pharmacotherapy. Knowing that brain alterations in cannabinoid receptors and endocannabinoids are strongly associated with the development of psychotic symptoms, the use of selective compounds that regulate their levels may represent a promising avenue for schizophrenia research (Kucerova et al., 2014, Fakhoury, 2016). As it turned out, modulating the

Conclusion

Despite significant progress in research, schizophrenia remains a debilitating disorder that presents a serious challenge to clinical therapeutics. As antipsychotics failed to meet expectations, the search for more effective therapies in still under way. The studies presented in this paper have shown that CBD could effectively reverse the positive, negative and cognitive symptoms of schizophrenia in animal models of the disease. In addition, findings from clinical trials suggest that CBD is

Conflict of interest

The author states that there is no conflict of interest.

Contributor

Marc Fakhoury.

Role of the funding source

Not available for this type of study.

Acknowledgments

The author is recipient of an award from the Natural Sciences and Engineering Research Council (NSERC) of Canada.

References (101)

  • P. Kwek et al.

    Modafinil disrupts prepulse inhibition in mice: strain differences and involvement of dopaminergic and serotonergic activation

    Eur. J. Pharmacol.

    (2013)
  • F.M. Leweke et al.

    Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use

    Schizophr. Res.

    (2007)
  • L. Li et al.

    Top-down modulation of prepulse inhibition of the startle reflex in humans and rats

    Neurosci. Biobehav Rev.

    (2009)
  • D.J. Lodge et al.

    Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia

    Behav. Brain Res.

    (2009)
  • D.T. Malone et al.

    Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats

    Pharmacol. Biochem. Behav.

    (2009)
  • M. Moller et al.

    Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine

    Brain Behav. Immun.

    (2013)
  • F.A. Moreira et al.

    Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

    Eur. J. Pharmacol.

    (2005)
  • C. Muguruza et al.

    Quantification of endocannabinoids in postmortem brain of schizophrenic subjects

    Schizophr. Res.

    (2013)
  • R.C. Pierce et al.

    The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?

    Neurosci. Biobehav Rev.

    (2006)
  • G. Remington

    Alterations of dopamine and serotonin transmission in schizophrenia

    Prog. Brain Res.

    (2008)
  • C.D. Schubart et al.

    Cannabidiol as a potential treatment for psychosis

    Eur. Neuropsychopharmacol.

    (2014)
  • L. Arseneault et al.

    Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study

    BMJ

    (2002)
  • B.S. Basavarajappa

    Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity

    Curr. Neuropharmacol.

    (2007)
  • M.M. Bergamaschi et al.

    Safety and side effects of cannabidiol, a Cannabis sativa constituent

    Curr. Drug Saf.

    (2011)
  • S. Bhattacharyya et al.

    Activation, internalization, and recycling of the serotonin 2A receptor by dopamine

    Proc. Natl. Acad. Sci. U. S. A.

    (2006)
  • S. Bhattacharyya et al.

    Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology

    Neuropsychopharmacology

    (2010)
  • D. Bhugra

    Migration, distress and cultural identity

    Br. Med. Bull.

    (2004)
  • D. Bhugra et al.

    Migration, cultural bereavement and cultural identity

    World Psychiatry

    (2005)
  • M.G. Bossong et al.

    Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum

    Psychopharmacol. Berl.

    (2015)
  • M.G. Bossong et al.

    Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum

    Neuropsychopharmacology

    (2009)
  • R. Brisch et al.

    The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue

    Front. Psychiatry

    (2014)
  • A. Caspi et al.

    Treatment-refractory schizophrenia

    Dialogues Clin. Neurosci.

    (2004)
  • P. Celada et al.

    The therapeutic role of 5-HT1A and 5-HT2A receptors in depression

    J. Psychiatry Neurosci.

    (2004)
  • N.A. Crossley et al.

    Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis

    Br. J. Psychiatry

    (2010)
  • D.C. D’Souza et al.

    The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis

    Neuropsychopharmacology

    (2004)
  • V.S. Dalton et al.

    Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex

    Neuropsychopharmacology

    (2011)
  • N. De Marchi et al.

    Endocannabinoid signalling in the blood of patients with schizophrenia

    Lipids Health Dis.

    (2003)
  • N.C. Di Pietro et al.

    Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action

    Pharmacopsychiatry

    (2007)
  • M. Dold et al.

    Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders

    Cochrane Database Syst. Rev.

    (2015)
  • R. Durst et al.

    Withdrawal from clozapine: the “rebound phenomenon”

    Isr. J. Psychiatry Relat. Sci.

    (1999)
  • M. Fakhoury

    Role of the endocannabinoid system in the pathophysiology of schizophrenia

    Mol. Neurobiol.

    (2016)
  • D.M. Fergusson et al.

    Cannabis dependence and psychotic symptoms in young people

    Psychol. Med.

    (2003)
  • M.A. Geyer et al.

    Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

    Psychopharmacol. Berl.

    (2001)
  • K.M. Gill et al.

    A novel alpha5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia

    Neuropsychopharmacology

    (2011)
  • N. Ginovart et al.

    Role of dopamine D(2) receptors for antipsychotic activity

    Handb. Exp. Pharmacol.

    (2012)
  • N. Ginovart et al.

    Chronic Delta(9)-tetrahydrocannabinol exposure induces a sensitization of dopamine D(2)/(3) receptors in the mesoaccumbens and nigrostriatal systems

    Neuropsychopharmacology

    (2012)
  • A. Giuffrida et al.

    Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms

    Neuropsychopharmacology

    (2004)
  • F.V. Gomes et al.

    The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors

    Psychopharmacol. Berl.

    (2011)
  • A.J. Goudie et al.

    Clozapine as a drug of dependence

    Psychopharmacol. Berl.

    (1999)
  • C. Guidali et al.

    Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine

    Int. J. Neuropsychopharmacol.

    (2011)
  • Cited by (0)

    View full text